EMEA Health and Science Correspondent
Kate's Feed
Nov 5, 2014

GSK hepatitis C shot shows promise, bodes well for Ebola vaccines

LONDON (Reuters) – A new hepatitis C vaccine from GlaxoSmithKline based on the same technology as an experimental Ebola shot being fast-tracked through human trials has shown promise in early clinical tests, prompting strong and broad immune responses.

Researchers testing the vaccine — the first hepatitis C vaccine to reach second stage clinical trials — said their results in a group of 15 healthy human volunteers showed it was very safe and well tolerated, and generated immune responses of a strength never seen before in a vaccine against this disease.

Nov 3, 2014

Interview: Melinda Gates backs contraception for healthier, wealthier future

LONDON, (Reuters) – Giving the millions of women who need it contraception and pregnancy advice will help avoid illness, disadvantage and poverty for current and future generations, Melinda Gates said on Monday.

The co-founder of the Bill & Melinda Gates Foundation told Reuters she is encouraged by progress in the past two years in putting family planning at the centre of woman and child health programmes, but says more needs to be done to ensure all women can choose freely whether and when to have children.

Nov 3, 2014

Melinda Gates backs contraception for healthier, wealthier future

LONDON, Nov 3 (Reuters) – Giving the millions of women who need it contraception and pregnancy advice will help avoid illness, disadvantage and poverty for current and future generations, Melinda Gates said on Monday.

The co-founder of the Bill & Melinda Gates Foundation told Reuters she is encouraged by progress in the past two years in putting family planning at the center of woman and child health programs, but says more needs to be done to ensure all women can choose freely whether and when to have children.

Oct 24, 2014

WHO says Ebola vaccine plans accelerating as trials advance

GENEVA/LONDON (Reuters) – Trials of Ebola vaccines could begin in West Africa in December, a month earlier than expected, and hundreds of thousands of doses should be available for use by the middle of next year, the World Health Organization said on Friday.

Vaccines are being developed and made ready in record time by drugmakers working with regulators, the U.N. health agency said, but questions remain about their safety and efficacy which can only be settled by full clinical trials.

Oct 24, 2014

WHO expects around 200,000 Ebola vaccine doses by mid-2015

GENEVA/LONDON (Reuters) – The World Health Organization (WHO) set out plans on Friday for speeding up development and deployment of experimental Ebola vaccines, saying hundreds of thousands of doses should be ready for use in West Africa by the middle of 2015.

The Geneva-based United Nations health agency confirmed that two leading vaccine candidates are in human clinical trials, and said another five experimental vaccines were also being developed and would begin clinical trials next year.

Oct 23, 2014

WHO concerned but ‘reasonably confident’ on international Ebola spread

GENEVA/LONDON (Reuters) – The World Health Organization (WHO) said on Thursday it was “reasonably confident” that the Ebola virus plaguing three West African countries had not spread into neighboring states.

Asked whether countries such as Guinea Bissau and Ivory Coast might have cases of the disease crossing their borders without knowing about or reporting them, WHO assistant director general Keiji Fukuda said he considered that unlikely.

Oct 23, 2014

Fixing ‘Ebolanomics’ in pursuit of vaccines and drugs

LONDON (Reuters) – As researchers from Africa to China to America race to develop vaccines and treatments to fight Ebola, health experts are grappling with the economics of a disease that until this year had been off the drug industry’s radar.

Whether or not effective drugs come in time to turn around the world’s worst epidemic of the virus ravaging three West African countries, the world will want stockpiles to protect against inevitable future outbreaks, experts say.

Oct 22, 2014

Drug-resistant tuberculosis at crisis levels, warns WHO

LONDON (Reuters) – Multi drug-resistant tuberculosis remains at crisis levels, with about 480,000 new cases this year, and various forms of the lung disease killed about 1.5 million people in 2013, the World Health Organization (WHO) said on Wednesday.

In recent years, the emergence of multi drug-resistant TB — a manmade problem caused by regular TB patients being given the wrong medicines, the wrong doses, or failing to complete their treatment — has posed an increasing global health threat.

Oct 20, 2014

Study shows exit screening vital to halting global Ebola spread

LONDON (Reuters) – Three Ebola-infected travelers a month would be expected to get on international flights from the West African countries suffering epidemics of the deadly virus if there were no effective exit screening, scientists said on Tuesday.

The three countries, Guinea, Liberia and Sierra Leone, do all check departing air passengers for fever, although the test cannot spot sufferers in the period before they show symptoms, which can be up to 21 days.

Oct 20, 2014

Cell transplant helps paralysed man walk with frame

LONDON, Oct 21 (Reuters) – A Bulgarian man who was paralysed
from the chest down in a knife attack can now walk with the aid
of a frame after receiving pioneering transplant treatment using
cells from his nose.

The technique, described as a breakthrough by a study in the
journal Cell Transplantation, involved transplanting what are
known as olfactory ensheathing cells into the patient’s spinal
cord and constructing a “nerve bridge” between two stumps of the
damaged spinal column.

    • About Kate

      "I cover health and science news for the region of Europe, Middle East and Africa -- from flu pandemics to the newest planetary discovery to the latest drug and research developments. I joined Reuters in 1993 and worked in London, Amsterdam and Frankfurt before moving to BBC television to work on European politics for Newsnight for 2 years. Since returning to Reuters, I have also worked as a parliamentary correspondent in Westminster and on the main news desk of the London bureau."
    • Follow Kate